Welcome to Bayside Health | Alfred. More information about Bayside Health can be found at baysidehealth.org.au

Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Updated: 1st of every month (unless a weekend)

Clear filter

663 clinical trials found

Clinical trials

APM001

A Randomised, Double-Blind, Parallel-Group,Placebo-Controlled, 60-Week, Phase II Clinical Trial of Three Re-Purposed Medications in Moderate Severity Parkinson’s Disease (ACTRN12620000560998)

No longer recruiting

APM002

A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled, 60-Week, Phase II Clinical Trial of Ambroxol and Doxycycline in Moderate Severity Parkinson’s Disease (ACTRN12623000843651)

No longer recruiting

App-delivered psychological treatment of IBS-in-IBD

Treatment of functional gut symptoms in patients with quiescent IBD and IBS - a single-blinded parallel trial assessing efficacy of app-delivered gut-directed hypnotherapy versus psycho-education (ACTRN12624000678594)

This trial will compare the effects of one of two app-delivered psychological programs on persistent gastrointestinal symptoms in people with inflammatory bowel disease in remission and persistent symptoms (termed IBS-in-IBD).

Currently recruiting

Aqua EFC17599

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis [AD] who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase [JAK] inhibitor treatment (NCT06241118)

Currently recruiting

Aravax - cashew/walnut/hazelnut

Discovery, design, and analysis of novel allergen peptide therapeutics (Trial Not Registered)

Blood samples from people with nut allergies – cashew, walnut and hazelnut. This is to research how a peptide immunotherapy can be developed for people with specific nut allergies. This is to overall support the discovery, design and future testing of peptide therapies.

Currently recruiting

ARGX-113-2315

A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Ocular Myasthenia Gravis [ADAPT oculus] (NCT06558279)

Currently recruiting

ARISE

Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy [CIDP]

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Currently recruiting

ARO-DM1-1001

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are =18 to = 65 Years (NCT06138743)

Currently recruiting

ARO-DUX4

A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients with Facioscapulohumeral Muscular Dystrophy Type 1 (NCT06131983)

Currently recruiting

AROATXN2

A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2 (NCT06672445)

No longer recruiting

ARTEMIS

ARTEMIS- Effects of Ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial infarction (105277)

No longer recruiting

ARTISTRY

An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens (NCT05502341)

No longer recruiting

ARTISTRY-2

Phase 3 Double-blind Multicenter Randomized Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Biktarvy® [Bictegravir/Emtricitabine/Tenofovir Alafenamide] in Virologically Suppressed People With HIV-1 [ARTISTRY 2] (NCT06333808)

No longer recruiting

ASCEND

ASCEND - A Randomised, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma (NCT05042128)

No longer recruiting

ASCOT

Australasian COVID-19 Trial [ASCOT]: An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess Different Treatment Regimens on the Clinical, Virological and Immunological Outcomes in Patients Diagnosed with SARS-CoV-2 Infection [COVID-19] (NCT04483960)

An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients with SARS-CoV-2 Infection (COVID-19).

Currently recruiting

ASKG315-101

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors (NCT05509985)

No longer recruiting

ASPIRE-AF

Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial (NCT03968393)

Currently recruiting

ASSURE

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) (NCT03301506)

No longer recruiting

AT02-001

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects with Systemic Amlyoidosis to Assess the Safety Tolerability, and Pharmacokinetics of AT-02 (NCT05521022)